Boston, MA (PressExposure) May 23, 2013 -- John M. Clerici, Principal at Tiber Creek Partners, will give a presentation titled "Overview of Non-Dilutive Funding for Antibiotics" at GTC's 10th Anti-Infectives Partnering and Deal-Making Conference on July 8-9, 2013 in Boston, MA.
Biotechnology companies are increasingly seeking to use non-dilutive capital from the U.S. Government, foreign governments, and non-governmental organizations as part of their commercialization objectives. Companies must have a full understanding of funding and procurement opportunities to communicate the advantages their technologies so that the message resonates most effectively with funding and purchasing decision-makers.
Private equity and venture capital firms are increasingly aware of the fact that legislation and policies established in the US and EU directly influences the value of their investments. It is critical for companies to undertake efforts in identifying and analyzing global government procurement trends as well as assessing the risks associated with investing in companies that receive U.S. federal and state funding and government contracts.
In the specific area of antibiotics, this approach is more important than any other area of biotechnology given the risks of development and the pricing pressure on new antibiotics, not to mention their finite life span for efficacy due to resistance. Thus, access to non-dilutive capital becomes critical. This talk will explore the sources of such capital, the experience of past applicants (both successful and unsuccessful) and prospects for future funding in this age of government austerity.
John Clerici is a founding Principal of Tiber Creek Partners, LLC. For over 14 years, John has been at the forefront in the creation of the public health preparedness sector, including helping large pharmaceutical and emerging biotechnology companies develop creative approaches to access non-dilutive capital to fund the development of biotechnology for emerging disease and engineered threats. Since 1999, John has assisted over three dozen companies in obtaining nearly $4 billion in funding for research, development and procurement of public health countermeasures to the Federal government, including the majority of the awards made under Project Bioshield, the U.S. Government's initiative for preparing the Nation against a bioterrorist attack. In 2006, John was instrumental in the passage of legislation creating the Biomedical Advanced Research and Development Authority (BARDA), which builds upon and improves Project BioShield. John began his career as a judge advocate with the U.S. Air Force where, among other assignments, he advised the Air Force Research Laboratory on the procurement of technology from research institutions throughout the United States, Europe and Asia. John earned his Juris Doctor from the University of North Carolina at Chapel Hill. He did his undergraduate work at the Catholic University of America, graduating summa cum laude.
GTC's Anti-Infectives Partnering & Deal Making Conference is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry. This event also provides a unique venue for attendees to learn about the anti-infective business trends, infectious disease markets, and novel technologies that shape up the industry.
This conference is part of our Infectious Diseases World Summit 2013 and will be held concurrently with the following two tracks:
11th Vaccines Research and Development: All Things Considered Conference 2nd Influenza Research & Development
For more information, please visit http://www.gtcbio.com/anti-infectives